Effect of Percutaneous Endoscopic Gastrostomy on Long-term Quality of Life in Patients with Locally Advanced Nasopharyngeal Carcinoma

Yun Xu  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Hewei Peng  
Fujian Medical University

Qiaojuan Guo  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Lanyan Guo  
Fujian Medical University

Jingfeng Zong  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Bijuan Chen  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Hanchuan Xu  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Jianji Pan  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Xian-E Peng  
Fujian Medical University

Shaojun Lin (✉ linshaojun@yeah.net)  
Fujian Medical University cancer Hospital: Fujian Provincial Cancer Hospital

Research Article

Keywords: nasopharyngeal carcinoma, percutaneous endoscopic gastrostomy, chemotherapy, nutritional support, quality of life

Posted Date: October 21st, 2021

DOI: https://doi.org/10.21203/rs.3.rs-893910/v1

License: ☑️  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Previous study revealed that prophylactic percutaneous endoscopic gastrostomy (PEG) maintain nutritional status of patients with locally advanced nasopharyngeal carcinoma (LA-NPC). We aimed to further investigate the effect of PEG on the long-term quality of life of patients with LA-NPC.

Methods: Patients with LA-NPC were selected and divided into PEG and non-PEG groups. The QLQ-C30 scores, incidence of adverse effects, weight and xerostomia recovery were compared between the two groups.

Results: No statistically significant difference in the scores of each QLQ-C30 scales between the two groups (P>0.05). The incidence of xerostomia was higher in the PEG group than in the non-PEG group (P=0.044), but no significant difference in the incidence of the remaining adverse effects as well as in weight and dry mouth recovery (P>0.05).

Conclusion: PEG seems not to have a detrimental effect on long-term quality of life, including the swallowing function of NPC patients.

Introduction

Nasopharyngeal carcinoma (NPC) is a malignant epithelial cancer prevalent in southern China. Radiotherapy is the primary treatment for NPC owing to its high sensitivity to radiation and the complex anatomy of the nasopharynx[1]. Most patients with NPC are in the locally advanced stage when diagnosed, at which point intensity-modulated radiotherapy (IMRT) with concurrent chemoradiotherapy (CCRT) is the standard treatment[2, 3]. IMRT can increase the survival of patients and decrease the damage to normal tissues[4–7]. The quality of life (QoL) and late toxicities have attracted more and more attention, along with the improved survival.

As a result of the side effects of radiotherapy and chemotherapy, patients with locally advanced nasopharyngeal carcinoma (LA-NPC) commonly suffer from varying degrees of malnutrition and poor QoL during CCRT[8–10]. Several studies have demonstrated the link between poor nutritional status and a lower rate of survival among patients with NPC[11–13]. Moreover, nutritional status proved to be independently associated with QoL in cancer patients[14–16]. As a result, enteral nutritional support is an effective tool for patients with LA-NPC to preserve their nutritional status during treatment, thereby ensuring a smooth treatment progression.

The nasogastric tube, percutaneous endoscopic gastrostomy (PEG), and surgical gastrostomy are commonly used methods to provide enteral nutritional support. Nasogastric tubes are only appropriate for patients who are unable to eat by mouth for a brief period of time (less than 30 days) but need nutritional support, while PEG is appropriate for patients who need long-term (more than 30 days) nutritional support. PEG is less invasive, easier to handle, has fewer complications, and is less costly than surgical gastrostomy, making it more accessible to patients[17]. Our previous study found that prophylactic PEG prior to CCRT, as well as aggressive enteral nutritional support, maintained the nutritional status of patients with LA-NPC during CCRT and improved treatment completion rates[18]. And these advantages can be translated into survival advantages for N3 NPC patients.[19]. However, the role of PEG in patients’ QoL is still controversial[20–29]. Prophylactic PEG before radiotherapy increases QoL in patients with head and neck cancer[21–24]. Some research, however, have indicated that prophylactic gastrostomy placement prior to radiotherapy for patients with head and neck cancer is associated with a higher incidence of dysphagia and a greater reliance on PEG nutritional support[25–29]. Moreover, studies on the impact of PEG on QoL in NPC patients are lacking. Hence, this study aims to investigate the impact of PEG on patients’ long-term QoL.

Patients And Methods

Patients and Study Design

Patients with pathologically confirmed progressive stage of primary nasopharyngeal carcinoma admitted to Fujian Cancer Hospital between June 1, 2010 and June 30, 2014 were included in this retrospective study. 133 NPC patients who had received prophylactic PEG feeding at the discretion of their doctors before beginning CCRT and 133 non-PEG patients who was matched based on age, gender, and tumor, node, and metastases level were recruited firstly.[18]. Further exclusion criteria were as follows: 1) By June 30,
2020, patients who had died, had a recurrence, or had metastasis. 2) Patients under the age of 18 at the time of the initial consultation. 3) Patients who failed to complete the QOL questionnaires. As shown in Fig. 1, a total of 148 NPC patients were finally enrolled in this study. The research was approved by the Fujian Cancer Hospital’s Ethics Review Committee, and all participants signed a written informed consent form.

**Radiation Treatment and Chemotherapy**

All patients received IMRT in combination with systemic chemotherapy. The radiotherapy was at a total dose of 68.8-81.75Gy (median, 70Gy) in 31–36 fractions (median, 33 fractions) for the primary tumor site. Except for three patients who received only two CCRT cycles, all patients were treated with cisplatin-based neoadjuvant chemotherapy (NACT) and CCRT. Detailed descriptions of IMRT and chemotherapy regimens have been published previously.[18]

**PEG Placement**

All patients were free of severe stomach and other gastrointestinal lesions, without any past history of aggressive liver disease, hepatic or kidney dysfunction, congestive heart failure, chronic malignancy, dementia, respiratory failure, and coma. The pull method was used to place all PEG tubes[30]. PEG tubes were placed before the start of radiotherapy and were removed only after the acute mucositis had disappeared and the patient was able to consume enough food orally. All patients and their families were fully informed of the potential side effects of radiotherapy, the efficacy of PEG and its expected advantages as well as possible risks before treatment.

**Data Collection**

The late adverse effects of radiotherapy were evaluated in accordance with CTCAE 4.0. To assess the QoL of patients, we used the validated and internationally accepted European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3 (EORTC QLQ-C30)[31]. The questionnaire comprises 30 questions, and is divided into 15 domains. There are five multi-item functional scales (bodily, cognitive, emotional, social and role functions), as well as three multi-item symptom scales (fatigue, pain, and nausea/emesis) and general QoL. Six single-item scales concerning dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties are also included. The items were graded on a 1–4 scale, with the exception of the general QoL issue, which was scored on a 1–7 scale. The mean score for each scale was calculated and transformed into a value between 0 and 100. Higher scores for functioning and general QoL suggest better functioning and general QoL, whereas higher scores for symptoms indicate worse outcomes. To optimize the response rate, questionnaires were evaluated by telephone interviews conducted by the same professional training investigator.

**Statistical Analyses**

The baseline characteristics of subjects were analyzed using the t test for normal continuous variables and Nonparametric Kruskal-Wallis test for non-normal continuous variables. The Chi-Square test or Fisher exact probability method was used to analyze qualitative data. SPSS, version 19.0.0.1(IBM SPSS, 2010, Chicago, IL, USA) was used for statistical analyses. All P values were two-tailed, and P values of 0.05 were considered statistically important.

**Results**

**Baseline Characteristics of the Study Population**

A total of 148 NPC patients (78 in the PEG group and 70 in the non-PEG group) were included in the study, based on the inclusion criteria. The male patients accounted for 107 (72.3%) of the total. The entire cohort's mean age at initial diagnosis was 43.27±11.34 years. In terms of gender, age, educational level, pathological type, clinical stage, T stage, N stage, and chemotherapy regimen, there were no statistically significant differences between the two groups (each P>0.05). All details are provided in Table 1.

Table 1

Baseline characteristics of the study population
| Variable                        | Non-PEG | PEG    | P value |
|--------------------------------|---------|--------|---------|
| Gender, n (%)                  |         |        | 0.714   |
| Male                           | 52(74.3)| 55(70.5)|         |
| Female                         | 18(25.7)| 23(29.5)|         |
| Age, mean±SD                   | 42.34±12.08| 44.10±10.65| 0.310   |
| Educational level, n (%)       |         |        | 0.193   |
| primary school and less than   | 18(25.7)| 21(26.9)|         |
| junior middle and high school  | 37(52.9)| 31(39.7)|         |
| junior college or above        | 15(21.4)| 26(33.3)|         |
| Pathology subtype, n (%)       |         |        | 0.599   |
| Keratinising squamous          | 2(2.9)  | 2(2.6) |         |
| Non-keratinising Undifferentiated squamous | 64(91.4)| 68(87.2)|         |
| Non-keratinising differentiated squamous | 4(5.7)  | 8(10.3)|         |
| Clinical stage, n (%)          |         |        | 0.612   |
| III                            | 42(60.0)| 41(52.6)|         |
| IVA                            | 18(25.7)| 22(28.2)|         |
| IVB                            | 10(14.3)| 15(19.2)|         |
| T stage, n (%)                 |         |        | 0.632   |
| T1                             | 4(5.7)  | 8(10.3)|         |
| T2                             | 13(18.6)| 16(20.5)|         |
| T3                             | 33(47.1)| 30(38.5)|         |
| T4                             | 20(28.6)| 24(30.8)|         |
| N stage, n (%)                 |         |        | 0.431   |
| N0                             | 1(1.4)  | 4(5.1) |         |
| N1                             | 18(25.7)| 15(19.2)|         |
| N2                             | 41(58.6)| 44(56.4)|         |
| N3                             | 10(14.3)| 15(19.2)|         |
| Regiments of CCRT              |         |        | 0.137   |
| Single agent                   | 67(95.7)| 69(88.5)|         |
| Two drugs                      | 3(4.3)  | 9(11.5)|         |

PEG, percutaneous endoscopic gastrostomy; CCRT, concurrent chemoradiotherapy.

**Comparison of Late Toxicities between Non-PEG and PEG Groups**

As shown in Table 2, the PEG group had a higher incidence of xerostomia than the non-PEG group (51.7% vs. 50%), and the difference was statistically significant (P=0.044). There were no statistically meaningful variations between the two groups of patients in terms of other distant adverse effects (all P>0.05). Incidence of neck fibrosis, xerostomia, hearing loss, tinnitus, and dysphagia were 41.9%, 50.7%, 68.9%, 42.6%, and 31.1%, respectively.
## Table 2

Comparison of late toxicities between non-PEG and PEG groups

| Variables                  | All, n(%) | Non-PEG | PEG | P value<sup>a</sup> |
|----------------------------|-----------|---------|-----|---------------------|
|                            |           | Grade 0, n(%) | Grade 1, n(%) | Grade 2, n(%) | Grade 3, n(%) | Grade 0, n(%) | Grade 1, n(%) | Grade 2, n(%) | Grade 3, n(%) |
| Neck fibrosis, n(%)        | 62(41.9)  | 47(67.1) | 19(27.1) | 4(5.7)         | 0(0)     | 39(50.0) | 35(44.9) | 2(2.6) | 2(2.6) | 0.052 |
| Xerostomia, n(%)           | 75(50.7)  | 35(50.0) | 22(31.4) | 13(18.6)       | 0(0)     | 38(48.7) | 32(41.0) | 5(6.4) | 3(3.8) | 0.044 |
| Worst hearing, n(%)        | 102(68.9) | 19(27.1) | 42(60.0) | 4(5.7)         | 5(7.1)   | 27(34.6) | 42(53.8) | 5(6.4) | 4(5.1) | 0.757 |
| Tinnitus, n(%)             | 63(42.6)  | 40(57.1) | 21(30.0) | 6(8.6)         | 3(4.3)   | 45(57.7) | 22(28.2) | 11(14.1) | 0(0) | 0.224 |
| Trismus, n(%)              | 10(6.8)   | 64(91.4) | 5(7.1)   | 0(0)           | 1(1.4)   | 74(94.9) | 4(5.1)   | 0(0) | 0(0) | 0.495 |
| Dysphagia, n(%)            | 46(31.1)  | 50(71.4) | 14(20.0) | 6(8.6)         | 0(0)     | 52(66.7) | 22(28.2) | 3(3.8) | 1(1.3) | 0.335 |
| Dysarthria, n(%)           | 11(7.4)   | 65(92.9) | 3(4.3)   | 0(0)           | 2(2.9)   | 72(92.3) | 5(6.4)   | 1(1.3) | 0(0) | 0.329 |
| Chewing, n(%)              | 22(14.9)  | 62(88.6) | 1(1.4)   | 7(10.0)        | 0(0)     | 64(82.1) | 2(2.6)   | 8(10.3) | 4(5.1) | 0.260 |
| Hoarseness, n(%)           | 9(6.1)    | 68(97.1) | 1(1.4)   | 0(0)           | 1(1.4)   | 71(91.0) | 3(3.8)   | 1(1.3) | 3(3.8) | 0.451 |
| Tongue dysfunction, n(%)   | 5(3.3)    | 67(95.7) | 1(1.4)   | 1(1.4)         | 1(1.4)   | 76(97.4) | 2(2.6)   | 0(0) | 0(0) | 0.480 |

<sup>a</sup> Fisher exact probability method.

PEG, percutaneous endoscopic gastrostomy.

## Results of the EORTC QLQ-C30

Data for the EORTC QLQ-C30 scales are presented in Table 3. The mean score of general QoL was 83.78±16.11. There were no significant differences between PEG and non-PEG group in the EORTC QLQ-C30 scales. Furthermore, after stratifying by age, no significant differences between the groups were observed (all \( P>0.05 \)) (Figure 2 and Figure 3).

| Variables                  | All, n(%) | Non-PEG | PEG | P value<sup>a</sup> |
|----------------------------|-----------|---------|-----|---------------------|
|                            |           | Grade 0, n(%) | Grade 1, n(%) | Grade 2, n(%) | Grade 3, n(%) | Grade 0, n(%) | Grade 1, n(%) | Grade 2, n(%) | Grade 3, n(%) |
| Neck fibrosis, n(%)        | 62(41.9)  | 47(67.1) | 19(27.1) | 4(5.7)         | 0(0)     | 39(50.0) | 35(44.9) | 2(2.6) | 2(2.6) | 0.052 |
| Xerostomia, n(%)           | 75(50.7)  | 35(50.0) | 22(31.4) | 13(18.6)       | 0(0)     | 38(48.7) | 32(41.0) | 5(6.4) | 3(3.8) | 0.044 |
| Worst hearing, n(%)        | 102(68.9) | 19(27.1) | 42(60.0) | 4(5.7)         | 5(7.1)   | 27(34.6) | 42(53.8) | 5(6.4) | 4(5.1) | 0.757 |
| Tinnitus, n(%)             | 63(42.6)  | 40(57.1) | 21(30.0) | 6(8.6)         | 3(4.3)   | 45(57.7) | 22(28.2) | 11(14.1) | 0(0) | 0.224 |
| Trismus, n(%)              | 10(6.8)   | 64(91.4) | 5(7.1)   | 0(0)           | 1(1.4)   | 74(94.9) | 4(5.1)   | 0(0) | 0(0) | 0.495 |
| Dysphagia, n(%)            | 46(31.1)  | 50(71.4) | 14(20.0) | 6(8.6)         | 0(0)     | 52(66.7) | 22(28.2) | 3(3.8) | 1(1.3) | 0.335 |
| Dysarthria, n(%)           | 11(7.4)   | 65(92.9) | 3(4.3)   | 0(0)           | 2(2.9)   | 72(92.3) | 5(6.4)   | 1(1.3) | 0(0) | 0.329 |
| Chewing, n(%)              | 22(14.9)  | 62(88.6) | 1(1.4)   | 7(10.0)        | 0(0)     | 64(82.1) | 2(2.6)   | 8(10.3) | 4(5.1) | 0.260 |
| Hoarseness, n(%)           | 9(6.1)    | 68(97.1) | 1(1.4)   | 0(0)           | 1(1.4)   | 71(91.0) | 3(3.8)   | 1(1.3) | 3(3.8) | 0.451 |
| Tongue dysfunction, n(%)   | 5(3.3)    | 67(95.7) | 1(1.4)   | 1(1.4)         | 1(1.4)   | 76(97.4) | 2(2.6)   | 0(0) | 0(0) | 0.480 |

a Fisher exact probability method.

PEG, percutaneous endoscopic gastrostomy.
Variables | Non-PEG, median (range) | PEG, median (range) | All, Mean±SD | P value
--- | --- | --- | --- | ---
Global health status/QoL | 83(8-100) | 83(25-100) | 83.78±16.11 | 0.826
Physical functioning | 100(53-100) | 100(53-100) | 94.19±11.88 | 0.322
Role functioning | 100(0-100) | 100(0-100) | 96.51±15.46 | 0.633
Emotional functioning | 100(50-100) | 100(25-100) | 89.47±15.23 | 0.707
Cognitive functioning | 83(0-100) | 83(33-100) | 83.00±19.49 | 0.178
Social functioning | 100(0-100) | 100(0-100) | 90.14±21.17 | 0.739
Fatigue | 0(0-33) | 0(0-100) | 14.86±21.71 | 0.169
Nausea and vomiting | 0(0-100) | 0(0-50) | 0.90±5.42 | 0.144
Pain | 0(0-100) | 0(0-33) | 2.25±10.41 | 0.249
Dyspnoea | 0(0-67) | 0(0-100) | 4.50±15.38 | 0.859
Insomnia | 0(0-100) | 0(0-100) | 13.96±25.50 | 0.242
Appetite loss | 0(0-67) | 0(0-100) | 4.73±15.56 | 0.980
Constipation | 0(0-100) | 0(0-67) | 5.86±16.37 | 0.727
Diarrhoea | 0(0-67) | 0(0-0) | 3.83±14.30 | 0.868
Financial difficulties | 0(0-67) | 0(0-0) | 9.91±21.46 | 0.683

PEG, percutaneous endoscopic gastrostomy; QoL, quality of life.

Comparison of Weight and Xerostomia Recovery between Non-PEG and PEG Groups

Compared with patients in the PEG group, more patients in the non-PEG group took more than a year to return to baseline weight and recover from xerostomia, but no statistically significant differences between groups was seen (all P>0.05) (Table 4).

Table 4

Comparison of weight and xerostomia recovery between non-PEG and PEG groups

| Variables                        | Non-PEG | PEG   | P value |
|----------------------------------|---------|-------|---------|
| Time to return to baseline weight|         |       | 0.425   |
| ≤1 years                         | 34(48.6)| 43(55.1)|
| >1 years                         | 36(51.4)| 35(44.9)|
| Time of recovery from xerostomia |         |       | 0.628   |
| ≤1 years                         | 19(27.1)| 24(30.8)|
| >1 years                         | 51(72.9)| 54(69.2)|

PEG, percutaneous endoscopic gastrostomy.

Discussion

Patients who underwent prophylactic PEG experienced significant improvements in nutritional status and QoL while also showing increased treatment adherence during radiotherapy. Nonetheless, among patients with head and neck cancer, the role of PEG in
terms of long-term QoL and adverse effects is debatable. In this study, xerostomia was more common in the PEG group than in the non-PEG group. The frequency of other adverse effects such as dysphagia did not vary statistically significantly between the two groups. There was no statistically significant difference between the two groups in terms of QoL. However, the patients’ high general QoL scores showed that both groups of patients had a decent general QoL. To our knowledge, this is the first research that examines the impact of prophylactic PEG on long-term QoL and adverse effects in NPC patients. PEG does not appear to have a detrimental effect on long-term QoL, including swallowing function, according to our findings.

Similar results were observed in several head and neck cancer studies[22–24]. Axelsosn et al[22] used a EORTC QLQ-head and neck 35 scale and a 5-level oral intake scale to test swallowing outcomes in a randomized study that included patients with head and neck cancer who were randomly assigned to one of two groups: prophylactic PEG or nutritional support according to clinical practice. The patients’ capacity to swallow foods did not vary between the groups, according to the findings. Prestwich et al.[23] retrospectively included 56 patients with head and neck cancer in two matched groups who received either a prophylactic gastrostomy tube (GT) or a nasogastric tube as required and used the MD Anderson Dysphagia Inventory questionnaire to assess swallowing outcomes. In line with our findings, there was no significant difference in long-term swallowing function between the groups. Another study conducted by Prestwich et al.[24] showed the same results, as well.

However, some studies indicated that prophylactic PEG increases the risk of long-term dysphagia[25–28]. Patients who received prophylactic GT before treatment had a higher incidence of GT dependence and stricture diagnosis than those who did not. The authors hypothesized that the high incidence of long-term GT dependency in patients may be due to atrophy of the muscles that control the swallowing process[25]. Oozeer et al.[26] performed another analysis that yielded the same findings. Prophylactic PEG tubes were independent predictors of PEG tube dependency at least 1 year after treatment in patients with head and neck cancer who received definitive chemoradiation, according to a retrospective review[27]. A retrospective study[28] supports the hypothesis that patients treated with PEG feeding have higher severe late dysphagia than patients treated with R-NG feeding. The convenience of PEG placement, according to the authors, can deter patients from working hard to become nutritionally independent after therapy is completed. The opposite was found in our research. There was no significant difference between PEG and non-PEG groups in terms of long-term QoL, including dysphagia. Unlike the studies above, only NPC patients were included in our study. During radiotherapy, we encouraged patients in PEG groups to do swallowing exercises like drinking. In addition, the PEG tube was removed after the acute mucositis has resolved, allowing for adequate food intake orally (approximately 4–6 weeks after the end of radical radiotherapy). Moreover, to avoid interference with recurrence and metastasis, only patients without progression were included in our analysis.

Using the EORTC QLQ-C30 scale to assess the QoL of NPC patients who survived more than two years, a study included 216 NPC survivors found that these patients had a slightly high incidence of dry mouth, fatigue, hearing loss, depression and anxiety, but had a good QoL[32]. Another randomized controlled trial[33] showed that the observation group (nutritional support) had a lower incidence of adverse effects and had better short-term outcomes and QoL than the control group, which was likely due to the patients’ improved nutritional status. Of the 148 patients in our study, 102 (68.9%) had hearing loss and 75 (50.7%) were troubled by xerostomia. Patients, however, had higher mean scores for overall QoL as well as the five major functions of somatic, social, task, emotional, and cognitive functioning, and lower scores for the remaining symptoms. The fact that all of our study participants received intensity-modulated radiotherapy may have contributed to their high QoL. Intensity-modulated radiotherapy, as compared to traditional radiotherapy, helps protect normal tissues, reduce the occurrence of long-term side effects, and increase patients’ long-term QoL[34–37]. The other possible reason may be that final analysis included only patients without progression. The presence of xerostomia was significantly higher in the PEG group compared to the non-PEG group (51.7% vs. 50%, P = 0.044). However, there was no significant difference in Grade > or = 2 xerostomia between groups.

There are several limitations to the current study. First, there was selection bias in this study since it was not a prospective randomized controlled trial and the decision to conduct PEG was based on the patients’ wishes. Second, investigators gathered information on patients’ QoL mostly through telephone follow-up inquiries, resulting in information bias. Bias may be minimized to some extent in this study because the questionnaire was filled out by the same professionally qualified investigator after interviewing the patients, item by item via telephone follow-up.

Conclusions
During concurrent chemoradiotherapy, prophylactic PEG enhanced the nutritional status of patients with LA-NPC, without any adverse consequences for long-term QoL, including swallowing function. It remains an active and effective nutritional intervention for patients with LA-NPC who are deficient in nutrition and are unable to successfully complete the treatment. Prospective studies are also required for further evidence.

**Abbreviations**

NPC, nasopharyngeal carcinoma; IMRT, intensity-modulated radiotherapy; CCRT, concurrent chemoradiotherapy; QoL, quality of life; LA-NPC, locally advanced nasopharyngeal carcinoma; PEG, percutaneous endoscopic gastrostomy; NACT, neoadjuvant chemotherapy; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3; GT, gastrostomy tube

**Declarations**

**Acknowledgements**

The authors would like to express their gratitude to all participants for their cooperation and to all staffs for recruiting subjects and their technical assistance.

**Fundings**

This work was supported by the Natural Science Foundation of Fujian Province (grant no. 2018J01275, by Jingfeng Zong), the Natural Science Foundation of Fujian Province (grant no. 2019Y0061, by Yun Xu), the Training project of young talents in health system of Fujian Province (grant no. 2020GGB013, by Yun Xu) and the Training project of young talents in health system of Fujian Province (grant no. 2020GGA014, by Qiaojuan Guo).

**Conflict of interest**

All the authors declare that there are no financial or other relationships that might lead to a conflict of interest of the present article.

**Availability of data**

The datasets used can be available from the corresponding author on reasonable request.

**Code availability**

None.

**Authors' contributions**

*Conceptualization*: Yun Xu and Shaojun Lin; *Methodology*: Hewei Peng and Xian-E Peng; *Formal analysis and investigation*: Yun Xu, Hewei Peng, Qiaojuan Guo, Lanyan Guo, Jingfeng Zong, Bijuan Chen and Hanchuan Xu; *Writing—original draft preparation*: Yun Xu and Hewei Peng; *Writing—review and editing*: Jianji Pan, Xian-E Peng and Shaojun Lin; *Funding acquisition*: Yun Xu, Qiaojuan Guo and Jingfeng Zong; *Supervision*: Xian-E Peng and Shaojun Lin.

**Ethics approval**
The research was carried out in compliance with the Declaration of Helsinki and approved by the Fujian Cancer Hospital's Ethics Review Committee.

**Consent to participate**

Informed consent was obtained from all subjects involved in the study.

**Consent for publication**

Written informed consent has been obtained from the patients to publish this paper.

**References**

1. Chen Y-P, Chan ATC, Le Q-T et al (2019) Nasopharyngeal carcinoma. The Lancet 394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
2. Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 16(4):1310–1317. doi:10.1200/JCO.1998.16.4.1310
3. Ho F, Tey J, Chia D et al (2018) Implementation of temporal lobe contouring protocol in head and neck cancer radiotherapy planning: A quality improvement project. Medicine 97(38):e12381. doi:10.1097/MD.0000000000012381
4. Chen Y-Y, Zhao C, Wang J et al (2011) Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with 5 years of follow-up. Cancer 117(13):2910–2916. doi:10.1002/cncr.25773
5. Du T, Xiao J, Qiu Z et al (2019) The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. PloS one 14(7):e0219611. doi:10.1371/journal.pone.0219611
6. Vergeer MR, Doornaert PAH, Rietveld DHF et al (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74(1):1–8. doi:10.1016/j.ijrobp.2008.07.059
7. Zhang B, Mo Z, Du W et al (2015) Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol 51(11):1041–1046. doi:10.1016/j.oraloncology.2015.08.005
8. Bahl M, Siu LL, Pond GR et al (2004) Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys 60(4):1127–1136. doi:10.1016/j.ijrobp.2004.05.011
9. Hua X, Chen L-M, Zhu Q et al (2019) Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 27(10):3759–3767. doi:10.1007/s00520-019-4643-5
10. Wei X, Chen L (2012) Correlation of nutritional status and quality of life in patients with locally advanced nasopharyngeal carcinoma after concurrent radiotherapy and chemotherapy. Chinese Journal of Oncology Prevention Treatment 4(02):200–203
11. Shen L-J, Chen C, Li B-F et al (2013) High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. PloS one 8(7):e68660. doi:10.1371/journal.pone.0068660
12. Li G, Gao J, Liu Z-G et al (2014) Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution. Head Neck 36(5):660–666. doi:10.1002/hed.23357
13. Zeng Q, Shen L-J, Guo X et al (2016) Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma. BMC Cancer 16:169. doi:10.1186/s12885-016-2214-4
14. Ravasco P, Monteiro-Grillo I, Vidal PM et al (2004) Cancer: disease and nutrition are key determinants of patients’ quality of life. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 12(4):246–252. doi:10.1007/s00520-003-0568-z
15. Xu Y, Zhang M, Li H et al (2020) Effects of different nutritional status on the incidence of adverse reactions of nasopharyngeal carcinoma patients during radiotherapy. Anti-tumor Pharmacy 10(05):585–588 + 593
16. Meng L, Wei J, Ji R et al (2019) Effect of Early Nutrition Intervention on Advanced Nasopharyngeal Carcinoma Patients Receiving Chemoradiotherapy. J Cancer 10(16):3650–3656. doi:10.7150/jca.33475
17. Bravo JG, Ide E, Kondo A et al (2016) Percutaneous endoscopic versus surgical gastrostomy in patients with benign and malignant diseases: a systematic review and meta-analysis. Clinics 71(3):169–178. doi:10.6061/clinics/2016(03)09
18. Xu Y, Guo Q, Lin J et al (2016) Benefit of percutaneous endoscopic gastrostomy in patients undergoing definitive chemoradiotherapy for locally advanced nasopharyngeal carcinoma. OncoTargets therapy 9:6835–6841. doi:10.2147/OTT.S117676
19. Xu Y, Chen M, Guo Q et al (2021) Percutaneous endoscopic gastrostomy can improve survival outcomes in patients with N3 nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy. Oral Oncol 121:105435. doi:10.1016/j.joraloncology.2021.105435
20. Locher JL, Bonner JA, Carroll WR et al (2011) Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr 35(3):365–374. doi:10.1177/0148607110377097
21. Silander E, Nyman J, Bove M et al (2012) Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck 34(1):1–9. doi:10.1002/hed.21700
22. Axelsson L, Silander E, Nyman J et al (2017) Effect of prophylactic percutaneous endoscopic gastrostomy tube on swallowing in advanced head and neck cancer: A randomized controlled study. Head Neck 39(5):908–915. doi:10.1002/hed.24707
23. Prestwich RJD, Teo MTW, Gilbert A et al (2014) Long-term swallow function after chemoradiotherapy for oropharyngeal cancer: the influence of a prophylactic gastrostomy or reactive nasogastric tube. Clin Oncol (R Coll Radiol (G B)) 26(2):103–109. doi:10.1016/j.clon.2013.10.005
24. Prestwich RJD, Murray LJ, Williams GF et al (2019) Impact of choice of feeding tubes on long-term swallow function following chemoradiotherapy for oropharyngeal carcinoma. Acta oncologica (Stockholm Sweden) 58(8):1187–1196. doi:10.1080/0284186X.2019.1609698
25. Chen AM, Li B-Q, Lau DH et al (2010) Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 78(4):1026–1032. doi:10.1016/j.ijrobp.2009.09.036
26. Oozeer NB, Corsar K, Glore RJ et al (2011) The impact of enteral feeding route on patient-reported long term swallowing outcome after chemoradiation for head and neck cancer. Oral Oncol 47(10):980–983. doi:10.1016/j.joraloncology.2011.07.011
27. Pohar S, Demarcantonio M, Whiting P et al (2015) Percutaneous endoscopic gastrostomy tube dependence following chemoradiation in head and neck cancer patients. Laryngoscope 125(6):1366–1371. doi:10.1002/lary.25117
28. Ward MC, Bhatia P, Nwizu T et al (2016) Impact of feeding tube choice on severe late dysphagia after definitive chemoradiotherapy for human papillomavirus-negative head and neck cancer. Head Neck 38(Suppl 1):E1054–E1060. doi:10.1002/hed.24157
29. Williams GF, Teo MTW, Sen M et al (2012) Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy? Oral Oncol 48(5):434–440. doi:10.1016/j.joraloncology.2011.11.022
30. Ponsky JL, Gauderer MW, Stellato TA (1983) Percutaneous endoscopic gastrostomy. Review of 150 cases. Archives of surgery (Chicago, Ill.: 1960) 118(8): 913–914. doi: 10.1001/archsurg.1983.01390080021006
31. Zhang X, Zheng Q, Hao Y et al (2013) Assessment of EORTC QLQ C30 /H&N35 in nasopharyngeal carcinoma patients quality of life. Journal of new medicine 44(07):467–471
32. Hong JS, Tian J, Han QF et al (2015) Quality of life of nasopharyngeal cancer survivors in China. Curr Oncol 22(3):e142–e147. doi:10.3747/co.22.2323
33. Xia B, Sun R (2018) Influence of nutritional support on nutritional indicators and quality of life in nasopharyngeal carcinoma patients undergoing radiotherapy. Chinese evidence-based nursing 4(09):841–845

34. Tribius S, Bergelt C (2011) Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer treatment reviews 37(7):511–519. doi:10.1016/j.ctrv.2011.01.004

35. Huang T-L, Chien C-Y, Tsai W-L et al (2016) Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck 38(Suppl 1):E1026–E1032. doi:10.1002/hed.24150

36. Gupta T, Kannan S, Ghosh-Laskar S et al (2018) Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. PloS one 13(7):e0200137. doi:10.1371/journal.pone.0200137

37. McDowell LJ, Rock K, Xu W et al (2018) Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 102(2):340–352. doi:10.1016/j.ijrobp.2018.05.060

Figures

![Flowchart of the study population. NPC, nasopharyngeal carcinoma; PEG, percutaneous endoscopic gastrostomy; CCRT, concurrent chemoradiotherapy.](image-url)
Figure 2

Comparison of quality of life in patients aged <45 years between non-PEG and PEG groups.

Figure 3

Comparison of quality of life in patients aged ≥45 years between non-PEG and PEG groups.